Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/6/2025

Adverse Reactions to Cancer Therapies

Hematologic Toxicity

  • Neutropenia occurs in 30-60% of patients, anemia in 3-11%, thrombocytopenia in 8-14%, leucopenia in 4-14%, and lymphopenia in up to 40% of patients when treated with R-CHOP regimen 1, 2
  • Myelosuppression is common when rituximab is administered as part of the R-CHOP regimen, with grade 3-4 neutropenia, anemia, thrombocytopenia, leucopenia, and lymphopenia occurring in patients 2

Infections

  • Infections occur in approximately 31% of patients, with bacterial infections being the most common (19%), followed by viral (10%) and fungal (1%) infections when treated with R-CHOP regimen 1, 2
  • Reactivation of hepatitis B is a significant risk in patients with positive HBsAg or anti-HBc, and rituximab is classified as a high-risk agent (≥10%) for hepatitis B reactivation 3
  • Patients with hepatitis B should receive prophylactic antiviral therapy and close monitoring 3

Gastrointestinal and Hepatic Toxicity

  • Nausea, vomiting, and general gastrointestinal distress occur in patients when treated with R-CHOP regimen 1
  • Elevation of liver enzymes (transaminases) occurs in patients when treated with R-CHOP regimen 1
  • Severe hepatotoxicity, including acute hepatitis and liver failure, occurs in rare cases 1

Dermatologic and Other Toxicity

  • Skin rash, paronychia, and pruritus occur in patients, and injection site reactions occur in approximately 47% of patients when treated with R-CHOP regimen 1
  • Fatigue, headache, dizziness, vertigo, musculoskeletal pain, asthenia, and general malaise occur in patients when treated with R-CHOP regimen 1
  • Peripheral neuropathy may occur due to vincristine, and may begin after the first cycle but is usually cumulative with subsequent cycles 4

Severe Adverse Reactions

  • Hypersensitivity reactions, including anaphylaxis, occur in rare cases when treated with R-CHOP regimen 1
  • Lupus-like reactions and demyelinating disorders occur in rare cases when treated with R-CHOP regimen 1
  • Cytokine release syndrome is a risk in patients with high tumor burden, and those with high IgM levels should be considered for prophylactic plasmapheresis 4, 5

Monitoring and Management

  • Regular monitoring of complete blood counts is recommended to detect early myelosuppression, as recommended by the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 4, 2
  • A complete dermatological evaluation should be performed before and during treatment, especially in patients at high risk of skin cancer 1
  • Regular monitoring of liver function is recommended 1
  • Premedication with diphenhydramine, acetaminophen, and corticosteroids, as well as gradual infusion and close monitoring, can help minimize infusion-related reactions, as recommended by the European Society for Medical Oncology 2, 6
  • The American College of Physicians recommends a multidisciplinary approach to managing adverse effects and preventing complications in patients receiving R-CHOP therapy 4
  • Elevated IgM levels ("IgM flare") can occur in 40-50% of patients, especially in those with Waldenström's macroglobulinemia, and may require plasmapheresis to prevent symptomatic hyperviscosity, as recommended by guideline societies 2, 6, 4
  • Prophylactic antibiotics and close monitoring are recommended for patients at high risk of infections, as recommended by the Infectious Diseases Society of America 3